<div id="readability-page-1">CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. The firm discussed positive findings from CRISPR’s American Heart Association presentation on CTX310, targeted at ANGPTL3 for a variety of cholesterol issues. […]</div>

CRISPR治療

<p>Citizens 重申了對 CRISPR Therapeutics AG 的市場優於大盤評級，並將其目標價格定為 86 美元，理由是儘管 Casgevy 的增長放緩，但 CRISPR 在美國心臟協會會議上關於 CTX310 的展示結果積極</p>

儘管 Casgevy 的增長放緩，Citizens 仍維持對 CRISPR Therapeutics（CRSP）的市場表現優於大盤的評級